(Q37936459)

25 August 2017

1 reference

title

Road to remission: a comprehensive review of therapy in uveitis (English)

1 reference

25 August 2017

1 reference

Sana S Siddique

1

1 reference

25 August 2017

Rajiv Shah

series ordinal

2

1 reference

25 August 2017

Ana M Suelves

series ordinal

3

1 reference

25 August 2017

Charles Stephen Foster

series ordinal

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

21 September 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

1 reference

25 August 2017

20

1 reference

25 August 2017

1497-1515

1 reference

25 August 2017

11

1 reference

Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts.

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Biodegradable intraocular therapies for retinal disorders: progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

New and emerging treatments for patients with uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Management of sympathetic ophthalmia with the fluocinolone acetonide implant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Use of methotrexate in the management of sight-threatening uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Low-dose methotrexate therapy for ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Methotrexate for ocular inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Pharmacotherapy of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Immunosuppressive Therapy for Severe Chronic Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Azathioprine for ocular inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Mycophenolate mofetil for ocular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Cyclosporine for ocular inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Cyclophosphamide for ocular inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Short-term chlorambucil for refractory uveitis in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Behçet's disease: a new target for anti-tumour necrosis factor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Use of sirolimus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

The efficacy of sirolimus in the treatment of patients with refractory uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Adverse events after intravitreal infliximab (Remicade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Retrospective case review of pediatric patients with uveitis treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Biological response modifier therapy for refractory childhood uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Intravitreal adalimumab for refractory uveitis-related macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Intravenous daclizumab for recalcitrant ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Daclizumab for treatment of birdshot chorioretinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Rituximab for treatment of ocular inflammatory disease: a series of four cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Intravenous immunoglobulin therapy for resistant ocular Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Interferons and their potential in the treatment of ocular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

IL-1 pathways in inflammation and human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Blocking interleukin-1 in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Biologics in the treatment of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.617741

10.1517/13543784.2011.617741

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference